parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in neutrophils	0.75
chemistry Open Targets	hard to drug	0.27
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 71	0.91
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 11577

MYO1F in dopamine neurons, braak-0.71 (p 0.032) → +0.26 (p 0.493)receipt 11584
MYO1F in microglia, braak-0.13 (p 0.739) → +0.17 (p 0.670)receipt 11583

receipt 11584: MYO1F in dopamine neurons, braak

power: full sample -0.18 (p 0.487, n 18), 95% CI -0.59 to +0.32. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.17 (p 0.504, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.14 (p 0.591, n 18). could be the mix.
skeptic: leave-one-out range -0.32 to -0.08, sign flips 0; without severely affected donors -0.18 (p 0.487, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MYO1F in dopamine neurons.

case closed: nothing better to follow up.

receipt 11583: MYO1F in microglia, braak

power: full sample +0.04 (p 0.861, n 18), 95% CI -0.43 to +0.50. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.04 (p 0.861, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.04 (p 0.861, n 18). could be the mix.
skeptic: leave-one-out range -0.10 to +0.16, sign flips 6; without severely affected donors +0.04 (p 0.861, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MYO1F in microglia.

case closed: nothing better to follow up.

loading the receipts